Autolus Therapeutics plc (AUTL): Capital Expenditures
$19.04M
Year ended 2025-12-31
$7.12M
Trailing 12 months to 2026-06-30
+20.7%
3-year compound annual growth
+5.3%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $19.04M | -13.7% | 2026-03-27, From 2025-01-01 |
| 2024-12-31 | $22.07M | +100.9% | 2026-03-27, From 2024-01-01 |
| 2023-12-31 | $10.99M | +1.3% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $10.84M | +22.4% | 2024-03-21, From 2022-01-01 |
| 2021-12-31 | $8.86M | -39.7% | 2024-03-21, From 2021-01-01 |
| 2020-12-31 | $14.68M | -20.0% | 2023-03-07, From 2020-01-01 |
| 2019-12-31 | $18.34M | n/a | 2022-03-10, From 2019-01-01 |
| No annual figure between 2018-09-30 and 2019-12-31. | |||
| 2018-09-30 | $9.12M | +217.1% | 2020-03-03, From 2017-10-01 |
| 2017-09-30 | $2.88M | +55.0% | 2020-03-03, From 2016-10-01 |
| 2016-09-30 | $1.85M | n/a | 2019-02-25, From 2015-10-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $19.04M | -13.7% |
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $6.47M | -52.8% |
| Compugen Ltd (CGEN) | 2025-12-31 | $306.0K | +159.3% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2024-12-31 | $0 | -100.0% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $3.83M | -22.8% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $4.83M | -33.8% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $536.0K | -85.8% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $564.0K | +45.0% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $155.0K | +10.7% |
Compare AUTL, RXRX, CGEN, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗